NATIONAL INSTITUTES OF HEALTH

NIH launches precision medicine trial, myeloMATCH, to test new treatment combinations for AML and MDS, aiming to accelerate tailored treatments through rapid genetic testing and targeted drug combinations.

President Biden and First Lady Jill Biden's White House Initiative on Women’s Health Research has secured nearly $1 billion for women’s health research, including $110 million in ARPA-H awards to accelerate transformative research in women’s health. These awards fund innovative projects addressing conditions such as endometriosis, brain disorders, chronic pain, preeclampsia, ovarian cancer, and migraines, aiming to improve prevention, diagnosis, and treatment for women.

BELA, an AI-based platform developed by Weill Cornell Medicine, assesses embryo chromosomal status without relying on embryologists' subjective assessments, potentially improving IVF efficiency. It analyzes time-lapse video images to predict euploidy or aneuploidy, showing higher accuracy than previous models and performing well across different datasets. A clinical trial is planned to further validate its effectiveness.

NIH's myeloMATCH trial tests precision medicine treatments for AML and MDS, aiming to accelerate tailored cancer therapies through genetic testing and targeted drug combinations.

A molecule targeting BCL6 and CDK9 proteins killed diffuse large B-cell lymphoma cells in lab tests without harming healthy mice. The approach aims to avoid treatment resistance by simultaneously activating multiple cell death signals, mimicking 'cell death by committee.' Researchers plan to test the molecule in mice with lymphoma and develop similar compounds for other cancer-driving proteins.

Dr. Sally Hodder, WVU's first elected member to the National Academy of Medicine, recognized for her work in infectious diseases and engaging rural communities in clinical trials.